Polaryx Therapeutics, Inc.
PLYX
$3.37
$0.092.59%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
4/23/2026
-
Globe Newswire
4/21/2026
-
Globe Newswire
4/15/2026
-
Globe Newswire
4/15/2026
-
MarketBeat
4/1/2026
-
Globe Newswire
3/21/2026
-
MarketBeat
3/18/2026
-
TipRanks Financial Blog
3/17/2026
-
Globe Newswire
3/12/2026
-
TipRanks Financial Blog
3/12/2026
-
The Fly
3/12/2026
-
Globe Newswire
3/2/2026
-
TipRanks Financial Blog
2/27/2026
-
MarketBeat
2/27/2026
-
Globe Newswire
2/27/2026
-
MarketBeat
2/18/2026
-
Benzinga
2/17/2026
-
Benzinga
2/17/2026
-
Globe Newswire
2/10/2026
-
Globe Newswire
2/5/2026
-
Globe Newswire
2/3/2026
-
Globe Newswire
2/2/2026
-
Globe Newswire
1/30/2026
-
Globe Newswire
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 24, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
201 940 7236
Address
South Tower
140 E Ridgewood Avenue - Suite 415
Paramus, NJ 07652
140 E Ridgewood Avenue - Suite 415
Paramus, NJ 07652
Country
Year Founded
Business Description
Sector
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal...
more